Business
PureTech Appoints Biocon Founder Kiran Shaw to BOD
PureTech Appoints Biocon Founder Kiran Shaw to BOD.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6953A\n PureTech Health PLC\n 01 October 2020\n \n \n \n \n 1 October 2020\n \n \n PureTech Health plc\n \n \n \n \n \n \n PureTech Appoints\n \n \n Kiran Mazumdar-Shaw, Founder and Chairperson of a Leading Global Biopharmaceutical Company, to Board of Directors\n \n \n \n \n \n \n \n \n PureTech Health plc\n \n \n \n (LSE: PRTC) (\"PureTech\"), a clinical stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, today announced the appointment of biotech entrepreneur Kiran Mazumdar-Shaw to its board of directors. Ms Shaw is an industry trailblazer who has spent her career surpassing societal expectations as the founder and chairperson of India's largest and a leading global biopharmaceutical company, Biocon Limited. Driven by a commitment to provide access to life-saving medicines worldwide, Ms Shaw brings extensive experience in biotherapeutics, strategic leadership, financial and business development and a dedication to improving patients' lives to PureTech's board of industry leaders.\n \n \n \n \n \n \"Kiran is a tremendously successful entrepreneur in healthcare and widely recognised as one of the most powerful and influential women in business. She also has a keen interest in improving the health of people around the world,\" said Christopher Viehbacher, chairman of PureTech's board of directors. \"Kiran brings a wealth of experience and knowledge to PureTech's board as we enter this next exciting chapter of growth.\"\n \n \n \n \n \n Ms Shaw is a pioneer of the biotechnology industry in India and a noted philanthropist who has devoted herself to building a sustainable model for delivering top-quality diabetes and cancer care at affordable prices. Since she founded Biocon, she has guided its growth from a leading bioenzymes company of India to a fully integrated and globally recognised multibillion-dollar biopharma company with extensive research efforts in oncology, diabetes and autoimmune disease. In addition to her leadership of Biocon, Ms Shaw chairs the Indian State of Karnataka's Vision Group on Biotechnology and is on the Advisory Council of the Indian government's Department of Biotechnology. \n She serves on the \n Board of Trustees at Massachusetts Institute of Techn...